International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 014-019
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
The Prognostic Importance of Leucocytosis, Thrombocytosis and Serum Vascular Endothelial Growth Factor (VEGF) Level in Inoperable Non-Small Cell Lung Cancer (NSCLC): A Match-Pair Analysis
Ahmet DEMIRKAZIK1, Mehmet ASIK2, Bulent YALCIN1, Mutlu DOGAN1, Abdullah BUYUKCELIK1, Orhan SENCAN1, Gungor UTKAN1, Hakan AKBULUT1, Fikri ICLI1
1Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, TURKEY
2Baskent University School of Medicine, Department of Endocrinology, Ankara, TURKEY
Keywords: Leucocytosis, Thrombocytosis, non-Small cell lung cancer, Prognostic factor, Serum VEGF
The aim of the study was to evaluate the relationship among leucocytosis, thrombocytosis and serum vascular endothelial growth factor (VEGF) levels and their prognostic value in patients with NSCLC. Fifty-five patients with histopathological and/or cytopathological diagnosed NSCLC were enrolled into the study. The patients were grouped as patients with leucocytosis (>10.000/mm3) and/or thrombocytosis (>400.000/mm3) (group 1), and others with none of them as a control group (group 2). Serum VEGF levels were measured by ELISA. Group 1 had three subgroups: patients with leucocytosis (group 1a), patients with thrombocytosis (group 1b) and patients with both of them (group 1c). Survival of the patients were analysed by Kaplan-Meier method. There was no survival difference between group 1 and 2, although there was a trend in favour of control group. The patients with higher levels of serum VEGF had a shorter survival than others who had lower levels, when the mean VEGF level of control group (206 pg/ml) was defined as cut-off value in group 1. The patients with leucocytosis and thrombocytosis had significantly higher VEGF levels when compared with control group (p= 0.022). No survival difference was observed for groups 1a, 1b and 1c when compared with control group. In conclusion, serum VEGF levels were significantly higher in patients who had leucocytosis and/or thrombocytosis although leucocytosis and/or thrombocytosis could not have been shown as a prognostic factor in patients with NSCLC. The association between serum VEGF and leucocytosis/thrombocytosis could not have been concluded as a cause or result.
Ahmet DEMIRKAZIK1, Mehmet ASIK2, Bulent YALCIN1, Mutlu DOGAN1, Abdullah BUYUKCELIK1, Orhan SENCAN1, Gungor UTKAN1, Hakan AKBULUT1, Fikri ICLI1
1Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, TURKEY
2Baskent University School of Medicine, Department of Endocrinology, Ankara, TURKEY
Keywords: Leucocytosis, Thrombocytosis, non-Small cell lung cancer, Prognostic factor, Serum VEGF
The aim of the study was to evaluate the relationship among leucocytosis, thrombocytosis and serum vascular endothelial growth factor (VEGF) levels and their prognostic value in patients with NSCLC. Fifty-five patients with histopathological and/or cytopathological diagnosed NSCLC were enrolled into the study. The patients were grouped as patients with leucocytosis (>10.000/mm3) and/or thrombocytosis (>400.000/mm3) (group 1), and others with none of them as a control group (group 2). Serum VEGF levels were measured by ELISA. Group 1 had three subgroups: patients with leucocytosis (group 1a), patients with thrombocytosis (group 1b) and patients with both of them (group 1c). Survival of the patients were analysed by Kaplan-Meier method. There was no survival difference between group 1 and 2, although there was a trend in favour of control group. The patients with higher levels of serum VEGF had a shorter survival than others who had lower levels, when the mean VEGF level of control group (206 pg/ml) was defined as cut-off value in group 1. The patients with leucocytosis and thrombocytosis had significantly higher VEGF levels when compared with control group (p= 0.022). No survival difference was observed for groups 1a, 1b and 1c when compared with control group. In conclusion, serum VEGF levels were significantly higher in patients who had leucocytosis and/or thrombocytosis although leucocytosis and/or thrombocytosis could not have been shown as a prognostic factor in patients with NSCLC. The association between serum VEGF and leucocytosis/thrombocytosis could not have been concluded as a cause or result.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |